Knight Therapeutics (TSE:GUD) Hits New 12-Month High – Here’s Why

Shares of Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high during trading on Wednesday. The stock traded as high as C$10.37 and last traded at C$10.29, with a volume of 137369 shares trading hands. The stock had previously closed at C$10.18.

Knight Therapeutics Stock Performance

The company has a market capitalization of C$992.14 million, a P/E ratio of 67.33, a PEG ratio of -1,013.50 and a beta of -0.29. The stock has a fifty day simple moving average of C$9.77 and a 200-day simple moving average of C$8.75. The company has a quick ratio of 1.79, a current ratio of 2.28 and a debt-to-equity ratio of 4.29.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, August 6th. The company reported C($0.03) earnings per share (EPS) for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%.The firm had revenue of C$143.97 million for the quarter. Equities analysts forecast that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.